| Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. | |
| | |
MedLine Citation:
|
PMID: 17938987 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis-osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-alpha) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-alpha blockade therapy. |
| | |
Authors:
|
Francisca Sabugo; Claudio Liberman; Juan Pablo Niedmann; Lilian Soto; Miguel Cuchacovich |
Related Documents
:
|
2696577 - Nanophthalmos in sisters, one with exfoliation syndrome. 10811097 - Combined exfoliation and pigment dispersion: paradigm of an overlap syndrome. 1583647 - Evidence that rieger syndrome maps to 4q25 or 4q27. 2508477 - Glaucoma in the maroteaux-lamy syndrome. 15980937 - A case of sjögren's syndrome with acute transverse myelitis and polyneuropathy in a pa... 9717367 - Pseudologia fantastica, factitious disorder and impostership: a deception syndrome. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2007-10-16 |
Journal Detail:
|
Title: Clinical rheumatology Volume: 27 ISSN: 0770-3198 ISO Abbreviation: Clin. Rheumatol. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-12 Completed Date: 2008-06-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8211469 Medline TA: Clin Rheumatol Country: Belgium |
Other Details:
|
Languages: eng Pagination: 533-5 Citation Subset: IM |
Affiliation:
|
Rheumatology Section, Department of Medicine, Clinical Hospital, University of Chile, Independencia, Santiago, Chile. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acquired Hyperostosis Syndrome
/
drug therapy* Adult Antibodies, Monoclonal / therapeutic use* Antirheumatic Agents / therapeutic use* Dose-Response Relationship, Drug Humans Hypothyroidism / drug therapy* Male Remission Induction Thyroxine / therapeutic use* Tumor Necrosis Factor-alpha / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 7488-70-2/Thyroxine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fracture risk remains reduced one year after discontinuation of risedronate.
Next Document: Oral bisphosphonates in treatment of transient osteoporosis.